ARCHIVES

Bad News for EPO Products Brings FDA Scrutiny, Payment Curbs. FDA Issues Alert to Doctors.

This article is from The Cancer Letter archive.

Vol. 33 No. 07 | February 23, 2007

Download PDF Visit The Full Archive

Related Articles

ASCO President Swain: “Shattering Impact on Cancer Enterprise”

February 15, 2013

Velcade Plus Dexamethasone Provides 20% Response In First-Line Treatment

December 29, 2006

NIH Guidelines Define Eligible Research Using Stem Cells.

September 8, 2000

Reed To Leave NCI Next Year; Allegra Moves To Extramural Side; Ozer Heads Okla. Center.

July 21, 2000

In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up

February 22, 2013

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975